摘要
目的观察苍附导痰丸加味联合西药治疗痰浊内阻型非酒精性脂肪性肝炎(NASH)的临床疗效。方法选取2022年1月—2023年12月在本院确诊为痰浊内阻型NASH的患者96例,按随机数字表法分为对照组和观察组,每组48例。对照组予多烯磷脂酰胆碱胶囊口服,2粒/次,3次/d。观察组在对照组治疗的基础上加用中药颗粒剂苍附导痰丸加味冲服,1剂/d。2组疗程均为12周。对比2组治疗前后生化指标(ALT、AST、GGT、TC、TG)、肝脏脂肪含量[受控衰减参数(CAP)值]、中医证候积分,观察肝脏脂肪含量疗效、中医证候疗效及安全性。结果治疗12周,2组生化指标均较治疗前均降低(P<0.05),且观察组GGT、TC、TG低于对照组(P<0.05)。治疗后,对照组、观察组CAP均较治疗前降低(P<0.05),且观察组低于对照组。观察组肝脏脂肪含量治疗总有效率高于对照组(P<0.05)。治疗后,对照组、观察组中医证候积分均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。观察组中医证候治疗总有效率为95.8%,高于对照组的81.3%(χ^(2)=5.031,P<0.05)。2组安全性指标检测无异常,且治疗过程中均未出现发热、皮疹、恶心呕吐等不适症状。结论苍附导痰丸加味联合西药可改善痰浊内阻型NASH患者肝功能、降低肝脏脂肪含量、改善中医证候,且安全性较高。
Objective To observe the clinical efficacy of modified Cangfu Daotan Pills combined with western medicine in the treatment of non-alcoholic steatohepatitis(NASH)with phlegm-turbid internal obstruction syndrome.Methods Ninety-six patients diagnosed with phlegm-turbid internal obstruction type NASH atThe First People’s Hospital of Huzhoufrom January 2022 to December 2023 were randomly divided into a control group and an observation group according to the random number table method,with 48 cases in each group.The control group received oral polyene phosphatidylcholine capsules(2 capsules per dose,three times daily).The observation group was given modified Cangfu Daotan Pills granules in addition to the control group treatment,administered once daily.The treatment duration for both groups was 12 weeks.Biochemical indices(ALT,AST,GGT,TC,TG),liver fat content[controlled attenuation parameter(CAP)value],traditional Chinese medicine(TCM)syndrome scores,efficacy of liver fat content,TCM syndrome efficacy,and safety of the two groups were compared before and after treatment.Results After 12 weeks of treatment,biochemical indices in both groups were significantly decreased compared to baseline(P<0.05),with GGT,TC,and TG levels in the observation group significantly lower than those in the control group(P<0.05).CAP values decreased significantly in both groups after treatment(P<0.05),with the observation group showing lower CAP values than the control group.The total effective rate of liver fat content improvement was higher in the observation group than in the control group(P<0.05).TCM syndrome scores were significantly reduced in both groups after treatment(P<0.05),with the observation group scoring lower than the control group(P<0.05).The total effective rate of TCM syndrome treatment was 95.8%in the observation group,higher than 81.3%in the control group(χ^(2)=5.031,P<0.05).Safety indicators showed no abnormalities in either group,and no adverse symptoms such as fever,rash,nausea,or vomiting were observed during treatment.Conclusion Modified Cangfu Daotan Pills combined with Western medicine can improve liver function,reduce liver fat content,and alleviate TCM syndromes in patients with phlegm-turbid internal obstructiontype NASH,with a high safety profile.
作者
余松
何杰
赵秋凤
YU Song;HE Jie;ZHAO Qiufeng(Department of Infectious Diseases,The First People's Hospitalof Huzhou,Huzhou 313000,China;Department of Hepatobiliary and Pancreatic Surgery,The First People's Hospital of Huzhou,Huzhou 313000)
出处
《北京中医药》
2025年第6期721-724,共4页
Beijing Journal of Traditional Chinese Medicine
基金
湖州市科学技术局公益性应用研究项目(2021GY10)。
关键词
苍附导痰丸
非酒精性脂肪性肝炎
痰浊内阻型
Cangfu Daotan Pills
non-alcoholic steatohepatitis
phlegm-turbid internal obstruction type
